Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gynecologic and colorectal cancer tumors. It also develops RMC-5845, a selective inhibitor of SOS1, a protein that converts RAS (OFF) to RAS (ON) in cells; and RMC-5552, a hyperactivated selective inhibitor of mTORC1 signaling in tumors. In addition, the company is developing RMC-6291, a mutant-selective inhibitor of KRASG12C(ON) and NRASG12C(ON); and RMC-6236, a RAS-selective inhibitor of multiple RAS(ON) variants. Further, it develops RAS(ON) Inhibitors targeting KRASG13C(ON) and KRASG12D(ON). Revolution Medicines, Inc. has a collaboration agreement with Sanofi for the research and development of SHP2 inhibitors, including RMC-4630. The company was incorporated in 2014 and is headquartered in Redwood City, California.
IPO Year: 2020
Exchange: NASDAQ
Website: revmed.com
Date | Price Target | Rating | Analyst |
---|---|---|---|
7/16/2024 | $46.00 → $62.00 | Buy | Needham |
7/12/2024 | $52.00 | Overweight | Barclays |
7/8/2024 | $63.00 | Buy | Jefferies |
4/12/2024 | $36.00 → $46.00 | Buy | Needham |
4/10/2024 | $36.00 → $48.00 | Outperform → Strong Buy | Raymond James |
3/11/2024 | $43.00 | Overweight | Piper Sandler |
1/5/2024 | $31.00 → $34.00 | Neutral → Buy | BofA Securities |
1/4/2024 | $41.00 | Outperform | Wedbush |
11/16/2023 | $30.00 | Outperform | Raymond James |
2/28/2023 | $32.00 → $38.00 | Neutral → Overweight | JP Morgan |
144 - Revolution Medicines, Inc. (0001628171) (Subject)
144 - Revolution Medicines, Inc. (0001628171) (Subject)
144 - Revolution Medicines, Inc. (0001628171) (Subject)
144 - Revolution Medicines, Inc. (0001628171) (Subject)
144 - Revolution Medicines, Inc. (0001628171) (Subject)
144 - Revolution Medicines, Inc. (0001628171) (Subject)
424B5 - Revolution Medicines, Inc. (0001628171) (Filer)
10-Q - Revolution Medicines, Inc. (0001628171) (Filer)
8-K - Revolution Medicines, Inc. (0001628171) (Filer)
144 - Revolution Medicines, Inc. (0001628171) (Subject)
4 - Revolution Medicines, Inc. (0001628171) (Issuer)
4 - Revolution Medicines, Inc. (0001628171) (Issuer)
4 - Revolution Medicines, Inc. (0001628171) (Issuer)
4 - Revolution Medicines, Inc. (0001628171) (Issuer)
4 - Revolution Medicines, Inc. (0001628171) (Issuer)
4 - Revolution Medicines, Inc. (0001628171) (Issuer)
4 - Revolution Medicines, Inc. (0001628171) (Issuer)
4 - Revolution Medicines, Inc. (0001628171) (Issuer)
4 - Revolution Medicines, Inc. (0001628171) (Issuer)
4 - Revolution Medicines, Inc. (0001628171) (Issuer)
SC 13G/A - Revolution Medicines, Inc. (0001628171) (Subject)
SC 13G/A - Revolution Medicines, Inc. (0001628171) (Subject)
SC 13G/A - Revolution Medicines, Inc. (0001628171) (Subject)
SC 13G/A - Revolution Medicines, Inc. (0001628171) (Subject)
SC 13G/A - Revolution Medicines, Inc. (0001628171) (Subject)
SC 13G/A - Revolution Medicines, Inc. (0001628171) (Subject)
SC 13G/A - Revolution Medicines, Inc. (0001628171) (Subject)
SC 13G/A - Revolution Medicines, Inc. (0001628171) (Subject)
SC 13G - Revolution Medicines, Inc. (0001628171) (Subject)
SC 13G/A - Revolution Medicines, Inc. (0001628171) (Subject)
Barclays analyst Peter Lawson maintains Revolution Medicines (NASDAQ:RVMD) with a Overweight and raises the price target from $52 to $54.
Oppenheimer analyst Jay Olson maintains Revolution Medicines (NASDAQ:RVMD) with a Outperform and raises the price target from $45 to $55.
B of A Securities analyst Alec Stranahan maintains Revolution Medicines (NASDAQ:RVMD) with a Buy and raises the price target from $48 to $55.
As of July 16, 2024, three stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions. The RSI is a momentum indicator, which compares a stock’s strength on days when prices go up to its strength on days when prices go down. When compared to a stock’s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered overbought when the RSI is above 70, according to Benzinga Pro. Here's the latest list of major overbought players in this sector. Aveanna Healthcare Holdings Inc (NASDAQ:AVAH) On May 9, Aveanna Healthcare posted a narrowe
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Mizuho raised the price target for Microsoft Corporation (NASDAQ:MSFT) from $450 to $480. Mizuho analyst Gregg Moskowitz maintained an Outperform rating. Microsoft shares gained 0.1% to close at $453.96 on Monday. See how other analysts view this stock. HC Wainwright & Co. boosted the price target for Revolution Medicines, Inc. (NASDAQ:RVMD) from $44 to $56. HC Wainwright & Co. analyst Robert Burns maintained a Buy rating. Revolution Medicines shares gained 1.9% to close at $46.00 on Monday. See ho
HC Wainwright & Co. analyst Robert Burns maintains Revolution Medicines (NASDAQ:RVMD) with a Buy and raises the price target from $44 to $56.
Needham analyst Ami Fadia maintains Revolution Medicines (NASDAQ:RVMD) with a Buy and raises the price target from $46 to $62.
Barclays analyst Peter Lawson initiates coverage on Revolution Medicines (NASDAQ:RVMD) with a Overweight rating and announces Price Target of $52.
Original research published in Cancer Discovery reveals a RAS(ON) multi-selective inhibitor exhibited robust anti-tumor activity alone or in combination with a RAS(ON) G12C-selective inhibitor in preclinical models of difficult-to-treat KRAS-mutated non-small cell lung cancer (NSCLC) Results also highlight that, in contrast to mutant-selective RAS inhibition, broad-spectrum, reversible RAS-GTP inhibition with a RAS(ON) multi-selective inhibitor alone drove durable anti-tumor activity in these models with infrequent resistance occurrence and the potential for emergence of rare persister, slow cycling cellsREDWOOD CITY, Calif., July 11, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (NASD
Shares of Helen of Troy Limited (NASDAQ:HELE) fell sharply during Tuesday's session after the company reported soft first-quarter earnings and lowered its FY25 guidance. Helen of Troy reported quarterly earnings of 99 cents per share which missed the analyst consensus estimate of $1.59. The company reported quarterly sales of $416.85 million which missed the analyst consensus estimate of $446.22 million, according to data from Benzinga Pro. Helen of Troy shares dipped 30.3% to $62.06 on Tuesday. Here are some other stocks moving in today’s mid-day session. Gainers Soligenix, Inc. (NASDAQ:SNGX) shares jumped 195% to $5.90 after the company announced interim results for extende
Circle Pharma, a company focused on developing macrocycle therapeutics against targets previously considered to be undruggable, has appointed Stephen Kelsey as an independent member of its Board of Directors. Dr. Kelsey has extensive experience in oncology clinical development. He currently serves as president, head of research and development and chief medical officer at Revolution Medicines (NASDAQ:RVMD), and previously held roles including president of Onkaido Therapeutics, the oncology-focused unit of Moderna (NASDAQ:MRNA), senior vice president of new products at Medivation (acquired by Pfizer (NYSE: PFE)), executive vice president and chief medical officer at Geron Corporation (NASDAQ
REDWOOD CITY, Calif., July 13, 2022 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (NASDAQ:RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today announced the appointment of Lorence Kim, M.D., to its board of directors. Dr. Kim has made significant contributions across the biotechnology and financial industries during his career at Moderna and Goldman Sachs. He has extensive operational expertise and an extraordinary track record in raising capital for high-growth health care companies. Dr. Kim will serve as an independent director for the remaining term of Neil Exter, who is stepping down after serving as a director most recently since 2019
REDWOOD CITY, Calif., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (NASDAQ:RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced its financial results for the quarter ended June 30, 2024, and provided an update on corporate progress. The company continues making progress on its 2024 development priorities: Advancing its RAS(ON) multi-selective inhibitor RMC-6236 into monotherapy pivotal trials. Pancreatic cancer: The company recently provided updated data on the clinical safety, tolerability and antitumor activity in patients with pancreatic ductal adenocarcinoma (PDAC) from its ongoing RMC-6236 mon
REDWOOD CITY, Calif., July 31, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (NASDAQ:RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that it will report financial results for the second quarter 2024 on Wednesday, August 7, 2024, after market close. At 4:30 p.m. Eastern Time that day (1:30 p.m. Pacific Time), Revolution Medicines' senior management team will host a webcast to discuss the financial results for the quarter and provide an update on corporate progress. To listen to the live webcast, or access the archived webcast, please visit: https://ir.revmed.com/events-and-presentations. Following the live
REDWOOD CITY, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (NASDAQ:RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced its financial results for the quarter ended March 31, 2024, and provided an update on corporate progress. The company continues making progress on its 2024 development priorities: Advancing its RAS(ON) multi-selective inhibitor RMC-6236 into monotherapy pivotal trials. As data from the first-in-human clinical study of RMC-6236 continue to mature, the company is preparing to advance RMC-6236 into randomized, controlled, monotherapy pivotal trials. The first trial expected to
REDWOOD CITY, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (NASDAQ:RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that it will report financial results for the first quarter 2024 on Wednesday, May 8, 2024, after market close. At 4:30 p.m. Eastern Time that day (1:30 p.m. Pacific Time), Revolution Medicines' senior management team will host a webcast to discuss the financial results for the quarter and provide an update on corporate progress. To listen to the live webcast, or access the archived webcast, please visit: https://ir.revmed.com/events-and-presentations. Following the live we
REDWOOD CITY, Calif., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (NASDAQ:RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced its financial results for the quarter and full year ended December 31, 2023, and provided an update on corporate progress. The company's strategic priorities for 2024 are focused on its pioneering RAS(ON) inhibitors: Advancing its RAS(ON) multi-selective inhibitor RMC-6236 into monotherapy pivotal trials. Studies in second line (2L) non-small cell lung cancer (NSCLC) and in 2L pancreatic ductal carcinoma (PDAC) are expected to begin in the second half of 2024.Expanding the
REDWOOD CITY, Calif., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (NASDAQ:RVMD), a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers, today announced that it will report financial results for the fourth quarter and full year 2023 on Monday, February 26, 2024, after market close. At 4:30 p.m. Eastern Time that day (1:30 p.m. Pacific Time), Revolution Medicines' senior management team will host a webcast to discuss the financial results for the quarter and full year, and provide an update on corporate progress. To listen to the live webcast, or access the archived webcast, please visit: https://ir.revmed.com/events-and-presentation
Promising clinical data for RMC-6236, a RASMULTI(ON) Inhibitor, and RMC-6291, a RASG12C(ON) Inhibitor, presented at AACR-NCI-EORTC ("Triple") and ESMO Meetings Acquisition of EQRx, Inc. expected to close later this month Revolution Medicines to hold webcast today at 4:30 p.m. Eastern Time REDWOOD CITY, Calif., Nov. 06, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (NASDAQ:RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today announced its financial results for the quarter ended September 30, 2023, and provided an update on corporate progress. Recent Highlights RMC-6236: Revolution Medicines presented promising anti-tumor activity
REDWOOD CITY, Calif., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (NASDAQ:RVMD), a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers, today announced that it will report financial results for the third quarter 2023 on Monday, November 6, 2023, after market close. At 4:30 p.m. Eastern Time that day (1:30 p.m. Pacific Time), Revolution Medicines' senior management team will host a webcast to discuss the financial results for the quarter and provide an update on corporate progress. To listen to the live webcast, or access the archived webcast, please visit: https://ir.revmed.com/events-and-presentations. Following the live webcast,
Company to provide clinical updates for RMC-6236 at Triple (AACR-NCI-EORTC) Meeting and ESMO (European Society for Medical Oncology) Congress 2023 and initial clinical findings for RMC-6291 at Triple Meeting Planning underway for one or more single agent pivotal trials with RMC-6236 and the first combination study of RMC-6236 and RMC-6291 Announced acquisition of EQRx, Inc. expected to add more than $1 billion in additional capital to balance sheet Webcast today at 4:30 p.m. Eastern Time REDWOOD CITY, Calif., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (NASDAQ:RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today announc
REDWOOD CITY, Calif., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (NASDAQ:RVMD), a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers, today announced that it will report financial results for the second quarter 2023 on Tuesday, August 8, 2023, after market close. At 4:30 p.m. Eastern Time that day (1:30 p.m. Pacific Time), Revolution Medicines' senior management team will host a webcast to discuss the financial results for the quarter and provide an update on corporate progress. To listen to the live webcast, or access the archived webcast, please visit: https://ir.revmed.com/events-and-presentations. Following the live webcast,
Needham reiterated coverage of Revolution Medicines with a rating of Buy and set a new price target of $62.00 from $46.00 previously
Barclays initiated coverage of Revolution Medicines with a rating of Overweight and set a new price target of $52.00
Jefferies initiated coverage of Revolution Medicines with a rating of Buy and set a new price target of $63.00
Needham reiterated coverage of Revolution Medicines with a rating of Buy and set a new price target of $46.00 from $36.00 previously
Raymond James upgraded Revolution Medicines from Outperform to Strong Buy and set a new price target of $48.00 from $36.00 previously
Piper Sandler initiated coverage of Revolution Medicines with a rating of Overweight and set a new price target of $43.00
BofA Securities upgraded Revolution Medicines from Neutral to Buy and set a new price target of $34.00 from $31.00 previously
Wedbush initiated coverage of Revolution Medicines with a rating of Outperform and set a new price target of $41.00
Raymond James initiated coverage of Revolution Medicines with a rating of Outperform and set a new price target of $30.00
JP Morgan upgraded Revolution Medicines from Neutral to Overweight and set a new price target of $38.00 from $32.00 previously
REDWOOD CITY, Calif., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (NASDAQ:RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced its financial results for the quarter ended June 30, 2024, and provided an update on corporate progress. The company continues making progress on its 2024 development priorities: Advancing its RAS(ON) multi-selective inhibitor RMC-6236 into monotherapy pivotal trials. Pancreatic cancer: The company recently provided updated data on the clinical safety, tolerability and antitumor activity in patients with pancreatic ductal adenocarcinoma (PDAC) from its ongoing RMC-6236 mon
REDWOOD CITY, Calif., July 31, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (NASDAQ:RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that it will report financial results for the second quarter 2024 on Wednesday, August 7, 2024, after market close. At 4:30 p.m. Eastern Time that day (1:30 p.m. Pacific Time), Revolution Medicines' senior management team will host a webcast to discuss the financial results for the quarter and provide an update on corporate progress. To listen to the live webcast, or access the archived webcast, please visit: https://ir.revmed.com/events-and-presentations. Following the live
Original research published in Cancer Discovery reveals a RAS(ON) multi-selective inhibitor exhibited robust anti-tumor activity alone or in combination with a RAS(ON) G12C-selective inhibitor in preclinical models of difficult-to-treat KRAS-mutated non-small cell lung cancer (NSCLC) Results also highlight that, in contrast to mutant-selective RAS inhibition, broad-spectrum, reversible RAS-GTP inhibition with a RAS(ON) multi-selective inhibitor alone drove durable anti-tumor activity in these models with infrequent resistance occurrence and the potential for emergence of rare persister, slow cycling cells REDWOOD CITY, Calif., July 11, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc.
REDWOOD CITY, Calif., July 08, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (NASDAQ:RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that it will host an investor webcast to provide an update on its RMC-6236 pancreatic ductal adenocarcinoma (PDAC) clinical development program. Speakers will include members of Revolution Medicines' management team, along with Brian M. Wolpin, M.D., M.P.H., professor of medicine at Harvard Medical School, and director of the Gastrointestinal Cancer Center and Robert T. & Judith B. Hale Chair in Pancreatic Cancer at Dana-Farber Cancer Institute. The webcast will take place a
REDWOOD CITY, Calif., June 05, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (NASDAQ:RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that Mark A. Goldsmith, M.D., Ph.D., the company's chief executive officer and chairman, will be a featured speaker in a fireside chat at the Goldman Sachs 45th Annual Global Healthcare Conference. Details of the company's participation are as follows: Goldman Sachs 45th Annual Global Healthcare Conference Conference Dates: June 10-13, 2024Fireside Chat Time/Date: 2:40 p.m. ET on Wednesday, June 12, 2024Location: Loews Miami Beach Hotel, Miami, FL To access a live webcast
REDWOOD CITY, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (NASDAQ:RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced its financial results for the quarter ended March 31, 2024, and provided an update on corporate progress. The company continues making progress on its 2024 development priorities: Advancing its RAS(ON) multi-selective inhibitor RMC-6236 into monotherapy pivotal trials. As data from the first-in-human clinical study of RMC-6236 continue to mature, the company is preparing to advance RMC-6236 into randomized, controlled, monotherapy pivotal trials. The first trial expected to
REDWOOD CITY, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (NASDAQ:RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that it will report financial results for the first quarter 2024 on Wednesday, May 8, 2024, after market close. At 4:30 p.m. Eastern Time that day (1:30 p.m. Pacific Time), Revolution Medicines' senior management team will host a webcast to discuss the financial results for the quarter and provide an update on corporate progress. To listen to the live webcast, or access the archived webcast, please visit: https://ir.revmed.com/events-and-presentations. Following the live we
REDWOOD CITY, Calif., April 09, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (NASDAQ:RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced the publication of a peer-reviewed research paper in Cancer Discovery. The scientific paper details the discovery and preclinical to clinical translation for RMC-6236, an investigational RAS(ON) multi-selective inhibitor, and includes exemplary case studies from the current Phase 1/1b clinical trial demonstrating the initial anti-tumor activity of RMC-6236. This original research was led by scientists at Revolution Medicines and conducted in collaboration with researchers fr
Two original papers in Nature highlight the discovery and translational implications of RMC-7977, a RAS(ON) multi-selective tri-complex inhibitor that exhibits unprecedented anti-tumor activity in preclinical models of RAS-mutant pancreatic ductal adenocarcinoma (PDAC) First paper demonstrates RMC-7977 successfully targets signaling by both mutant and wild-type forms of RAS to drive potent and durable inhibition of RAS-mutated cancers Second paper highlights translation-focused research with RMC-7977, which drives deep and durable anti-tumor activity, at well-tolerated doses, across a wide range of RAS-mutated PDAC preclinical models REDWOOD CITY, Calif., April 08, 2024 (GLOBE NEW
REDWOOD CITY, Calif., April 04, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (NASDAQ:RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that Mark A. Goldsmith, M.D., Ph.D., the company's chief executive officer and chairman, will be a featured speaker at the 23rd Annual Needham Healthcare Conference and the Stifel Targeted Oncology Forum. Details of the company's participation are as follows: 23rd Annual Needham Healthcare Conference Conference Dates: April 8-11, 2024Fireside Chat Time/Date: 1:30 – 2:10 p.m. ET on Thursday, April 11, 2024Location: Virtual; webcast available Stifel Targeted Oncology